The critical role of symptom experience on risk tolerance for gene therapy.
Journal articles
- Journal Article
Gonzalez Sepulveda, JM; Reed, SD; Telen, M
Published in: Blood Adv
November 12, 2024
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Blood Adv
DOI
EISSN
2473-9537
Publication Date
November 12, 2024
Volume
8
Issue
21
Start / End Page
5721 / 5722
Location
United States
Related Subject Headings
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gonzalez Sepulveda, J. M., Reed, S. D., & Telen, M. (2024). The critical role of symptom experience on risk tolerance for gene therapy. Blood Adv, 8(21), 5721–5722. https://doi.org/10.1182/bloodadvances.2024013811
Gonzalez Sepulveda, Juan Marcos, Shelby D. Reed, and Marilyn Telen. “The critical role of symptom experience on risk tolerance for gene therapy.” Blood Adv 8, no. 21 (November 12, 2024): 5721–22. https://doi.org/10.1182/bloodadvances.2024013811.
Gonzalez Sepulveda JM, Reed SD, Telen M. The critical role of symptom experience on risk tolerance for gene therapy. Blood Adv. 2024 Nov 12;8(21):5721–2.
Gonzalez Sepulveda, Juan Marcos, et al. “The critical role of symptom experience on risk tolerance for gene therapy.” Blood Adv, vol. 8, no. 21, Nov. 2024, pp. 5721–22. Pubmed, doi:10.1182/bloodadvances.2024013811.
Gonzalez Sepulveda JM, Reed SD, Telen M. The critical role of symptom experience on risk tolerance for gene therapy. Blood Adv. 2024 Nov 12;8(21):5721–5722.
Published In
Blood Adv
DOI
EISSN
2473-9537
Publication Date
November 12, 2024
Volume
8
Issue
21
Start / End Page
5721 / 5722
Location
United States
Related Subject Headings
- 3201 Cardiovascular medicine and haematology